Determinants of optimal adherence to antiretroviral therapy among people living with HIV/AIDS registered for antiretroviral therapy in Zimbabwe. Meidcal journal of Zambia

Abstract

Zimbabwe, among many other Sub-Saharan countries, has been highly affected by a huge HIV/AIDS burden. It was estimated that 1 242 768 people were HIV positive by 1 the end of 2012. The most affected group of people were those within the age range 15 to 49 years with an HIV prevalence of 14.9%. In 2012 the number of people estimated to have died due to HIV/AIDS in Zimbabwe was 45 621, thus indicating the serious impact the 1 condition still has. The World Health Organization 2010 guidelines recommended antiretroviral therapy (ART) for people with CD4 cell count less than or equal to 350, and patients with comorbid Tuberculosis and HIV 2 irrespective of their CD4 cell count. Evidence shows ARV therapy being able to lower an individual's viral load 2and allowing the body to restore some of its immunity. ART coverage in Zimbabwe for eligible individuals was standing at 78% for adults and 42% for children at the end 1 of 2011. Advancement has been made in coverage, however high level adherence is necessary in maintaining viral suppression and therefore reducing mortality.